Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Modern Principles of Treatment of Uncontrolled Hypertension

https://doi.org/10.20996/1819-6446-2019-15-5-736-741

Full Text:

Abstract

Despite the current possibilities of using different classes of antihypertensive drugs that effectively reduce blood pressure and significantly improve the long-term prognosis of patients, the problem of uncontrolled arterial hypertension has not lost its importance and its solution in a particular clinical situation often remains very difficult. The term "uncontrolled arterial hypertension" can be used in all cases where arterial pressure has not been achieved. The true prevalence of uncontrolled arterial hypertension has not been established, and its study is hampered primarily by the fact that not all patients initially receive antihypertensive therapy that meets generally accepted standards. Currently, the tactics of management of patients with uncontrolled hypertension involves the use of combinations of antihypertensive drugs. Rational combinations, according to the new recommendations for the diagnosis and treatment of arterial hypertension in 2018, remain a combination of blockers of the renin-angiotensin-aldosterone system – angiotensin-converting enzyme inhibitors or receptor blockers to angiotensin with a calcium antagonist or diuretic, preferably in one tablet. With the ineffectiveness of dual therapy needs to be assigned to a third antihypertensive drug. Among the most modern antihypertensive drugs can be considered a triple fixed combination of lisinopril, amlodipine and indapamide. All the components included in the composition of the drug, has proved its high efficiency and safety. Uncontrolled arterial hypertension remains one of the most urgent problems of modern cardiology. Many aspects of it are far from unambiguously interpreted solutions and standards. Until the end, the mechanisms of the formation of uncontrolled course of hypertension remain unexplored, which, in turn, leads to a restriction of the use of drug and non-drug methods in the treatment of this pathology. Rational choice of antihypertensive therapy regimens can significantly improve the quality of treatment of this category of patients.

About the Authors

V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Professor, Head of Chair of Faculty Therapy №2;

Director of Therapeutic Clinic of University Clinical Hospital №4, 

Trubetskaya ul. 8-2, Moscow, 119991 



A. I Tarzimanova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy №2,

Trubetskaya ul. 8-2, Moscow, 119991 



Z. O. Georgadze
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Associate Professor, Chair of Faculty Therapy №2,

Trubetskaya ul. 8-2, Moscow, 119991 



References

1. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.

2. Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.

3. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483. DOI:10.1161/CIR.0000000000000597.

4. Aksenova A.V., Esaulova T.E., Sivakova O.A., Chazova I.E. Resistant and refractory arterial hypertension: similarities and differences, new approaches to diagnosis and treatment. Systemic Hypertension. 2018;15(3):11-3 (In Russ.) DOI:10.26442/2075-082X_2018.3.11-13.

5. Chazova I.E., Zhernakova Y.V. Guidelines for diagnostics and treatment of hypertension 2018: European experts’ opinion. Systemic Hypertension. 2018;15(3):6-10 (In Russ.). DOI:10.26442/2075-082X_2018.3.6-10.

6. Semple P.F., Cumming A.M., Meredith P.A., et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45-50. DOI:10.1007/bf02125832.

7. Davis B.R., Culter J.A., Gordon D.J. Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Am J Hypertens.1996;9:342-60. DOI:10.1016/0895-7061(96)00037-4.

8. Malacco E., Santonastaso M., Vari N.A., et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26(6):855-65. DOI:10.1016/S0149-2918(04)90129-4.

9. Podzolkov V.I., Tarzimanova A.I. Lisinopril implication in the clinical practice. Rational Pharmacotherapy in Cardiology. 2010;6(4):565-8 (In Russ.) DOI:10.20996/1819-6446-2010-6-4-21-25.

10. Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertension. 1997; 30(1 Pt 1):140-5. DOI:10.1161/01.hyp.30.1.140.

11. Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997;95(6);1464-70. DOI:10.1161/01.cir.95.6.1464.

12. Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9. DOI:10.1097/00004872-200102000-00018.

13. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274): 1440-4. DOI:10.1136/bmj.321.7274.1440.

14. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349(9068):1787-92. DOI: 10.1016/S0140-6736(96)10244-0.

15. Roush G.C., Kaur R., Emst M.E. Diuretics: a review and update. J Cardiovasc Phamracol Ther. 2014;19(1):5-13. DOI:10.1177/10742 48413497257.

16. Roush G.C., Abdelfahah R., Song S., et al. Hydrochlorotiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head metaanalysis. J Hypertens. 2018;36(6):1247-55. DOI:10.1097/HJH.0000000000001691.

17. Podzolkov V.I., Dragomiretskaya N.A. The fixed combination of lisinopril and indapamide: optimization of cardio protection in hypertensive patients. Arterial Hypertension. 2018;24(4):459-68 (In Russ.) DOI:10.18705/1607-419Х-2018-24-4-459-468.

18. Kaplan N.M. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983- 984. DOI:10.1161/HWERTENSIONAHA.115.05138.

19. Musini V.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;(5):CD003824. DOI:10.1002/14651858. CD003824.pub2.

20. Olde Engberink R.H., Frenkel W.J., van den Bogaard B., et al. Effects of thiazide-type and thiazidelike diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension.2015;65(5):1033-40. DOI:10.1161/HYPERTENSIONAHA.114.052.

21. Liang W., Ma H., Cao L., et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a metaanalysis. J Cell Mol Med.2017;21(11):2634-42. DOI:10.1111/jcmm.13205.

22. Instructions for medical use of the drug Diroton® Plus. [cited by Sep 10, 2019]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d57c9ce3-239c-47f1-9d97-195471241054&t= (In Russ.)

23. Karpov Y. А. Triple combination of antihypertensive and lipid-lowering drugs is an effective reduction of the risk of cardiovascular complications in patients with arterial hypertension. Russian Medical Journal. 2015;27:1580-3 (In Russ.)

24. Pall D., Katona E., Juhasz M., et al. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil. 2006;147(32):1505-11.

25. Hernández R.H., Armas-Hernández M.J., Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther. 2003;10(6):409-14.

26. Jоrgensen B., Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J. 2003;145(6):1030-5. DOI:10.1016/S0002-8703 (03)00082-6.

27. Nissen S.E., Tuzcu E.M., Libby P., et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-25. DOI:10.1001/jama. 292.18.2217.

28. McCarty M.F. Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses. 2004;63(5):818-22. DOI:10.1016/j.mehy.2002.11.001.


For citation:


Podzolkov V.I., Tarzimanova A.I., Georgadze Z.O. Modern Principles of Treatment of Uncontrolled Hypertension. Rational Pharmacotherapy in Cardiology. 2019;15(5):736-741. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-5-736-741

Views: 27


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)